Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study. The future of the programme seems to be in ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

Takeda’s oral orexin receptor 2 agonist oveporexton could eventually hit peak sales between $2 billion and $3 billion, Takeda noted in its presentation. The “key” to the narcolepsy type 1 ...